• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GSK CEO predicts R&D success

GSK CEO predicts R&D success

July 29, 2011
CenterWatch Staff

GlaxoSmithKline CEO Andrew Witty said the pharmaceutical industry would contract in coming years and that the survivors would be those companies that solved the "equation" of how to squeeze the most profit from every dollar spent on R&D, according to the Philadelphia Inquirer.

"The market is signaling that it wants less—in total—spent on R&D, so the total amount of R&D will come down," Witty said. "That is what it is signaling through pricing and challenges it throws up in front of drug companies to get products to market.”

"Inevitably, you are now seeing, for the first time in history, a reduction in the total amount of industrial R&D done in the pharmaceutical space. But within that, there is clearly space for winners and losers,” continued Witty.

"There is tremendous opportunity for the few companies who solve the R&D equation," Witty said. "It's the companies who deliver multiple new products, not one or two, that address material clinical needs of patients and address the economic needs of the payers—so they are fairly priced.”

"My belief is that five to seven years from today, you'll see a significant number of companies retreat from the pharmaceutical space, one way or another. I think you'll see a few companies solve the problem, and I'm determined that GSK is going to be one of them."

Glaxo reported profits in the second quarter due to better-than-expected cost savings in its restructuring program and in tax changes related to its changing geography. Witty began restructuring the company four years ago, with part of the emphasis on emerging markets. He said 37% of sales were outside the U.S. and Europe, but the company also has facilities in India, China and Singapore.

Despite a 4% drop in revenue, the second-quarter profit was $1.8 billion, compared with a loss of $499 million in the second quarter of 2010.

Witty's restructuring included layoffs in the U.S. sales force. Another piece is moving the 1,300 employees to a new facility under construction. The 15½-year lease is a commitment to the city, but Glaxo also hopes to save money through less unused space.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing